Quarterly ResultMay 6, 2026, 07:07 AM
Immunocore Q1 Net Income Jumps 158% to $13.0M; Revenue Up 13.6%
AI Summary
Immunocore Holdings plc reported strong financial results for Q1 2026, with net income surging by 158.2% to $13.0 million and total revenue from therapy sales increasing by 13.6% to $106.7 million. The company highlighted the continued global expansion of its lead product, KIMMTRAK, now approved in 39 countries and commercially launched in over 30. Immunocore is also advancing its clinical pipeline and strategic priorities for 2026.
Key Highlights
- Net income for Q1 2026 surged 158.2% to $13.0 million.
- Basic net income per share increased 160% to $0.26.
- Total revenue from therapy sales grew 13.6% to $106.7 million.
- US revenue from therapy sales reached $67.4 million in Q1 2026.
- European revenue from therapy sales was $34.4 million in Q1 2026.
- Research and development expenses rose 8.2% to $61.1 million.
- KIMMTRAK is approved in 39 countries and commercially launched in over 30.
Price Impact
More from IMCR